PMID- 11964320
OWN - NLM
STAT- MEDLINE
DCOM- 20020619
LR  - 20231213
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 99
IP  - 9
DP  - 2002 May 1
TI  - Transient response to imatinib mesylate (STI571) in a patient with the ETV6-ABL 
      t(9;12) translocation.
PG  - 3465-7
AB  - We report the transient response of a patient with the ETV6-ABL fusion gene to 
      imatinib mesylate (STI571). A 38-year-old man was referred with an erroneous 
      diagnosis of Philadelphia-positive chronic myeloid leukemia in blastic 
      transformation for treatment with the ABL tyrosine kinase inhibitor, STI571. 
      Further investigation indicated that the patient in fact had acute myeloid 
      leukemia; no evidence of the Philadelphia translocation or BCR-ABL was found 
      using fluorescence in situ hybridization (FISH) or reverse 
      transcription-polymerase chain reaction. Detailed FISH analysis identified a 
      cryptic t(9;12) translocation, and molecular studies confirmed the presence of 
      the ETV6-ABL fusion transcript. Because the patient was gravely ill at 
      presentation, treatment was commenced immediately with STI571 monotherapy, 
      resulting in considerable initial improvement. However within 10 days the 
      patient's condition again deteriorated, and he required conventional 
      chemotherapy. This case has implications for the design of future studies using 
      STI571 in leukemias involving ABL-encoded fusion proteins other than BCR-ABL.
FAU - O'Brien, Stephen G
AU  - O'Brien SG
AD  - School of Clinical and Laboratory Sciences and the School of Biochemistry and 
      Genetics, University of Newcastle, United Kingdom. s.g.o'brien@ncl.ac.uk
FAU - Vieira, Sara A D
AU  - Vieira SA
FAU - Connors, Samantha
AU  - Connors S
FAU - Bown, Nick
AU  - Bown N
FAU - Chang, James
AU  - Chang J
FAU - Capdeville, Renaud
AU  - Capdeville R
FAU - Melo, Junia V
AU  - Melo JV
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (Benzamides)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (Piperazines)
RN  - 0 (Proto-Oncogene Proteins c-ets)
RN  - 0 (Pyrimidines)
RN  - 0 (Repressor Proteins)
RN  - 8A1O1M485B (Imatinib Mesylate)
SB  - IM
MH  - Acute Disease
MH  - Adult
MH  - Benzamides
MH  - *Chromosomes, Human, Pair 12
MH  - *Chromosomes, Human, Pair 9
MH  - DNA-Binding Proteins/*genetics
MH  - Genes, abl/*genetics
MH  - Humans
MH  - Imatinib Mesylate
MH  - Leukemia, Myeloid/diagnosis/drug therapy/genetics
MH  - Male
MH  - Oncogene Proteins, Fusion/genetics
MH  - Piperazines/*administration & dosage/pharmacology
MH  - Proto-Oncogene Proteins c-ets
MH  - Pyrimidines/*administration & dosage/pharmacology
MH  - Recurrence
MH  - Repressor Proteins/*genetics
MH  - *Translocation, Genetic
MH  - ETS Translocation Variant 6 Protein
EDAT- 2002/04/20 10:00
MHDA- 2002/06/20 10:01
CRDT- 2002/04/20 10:00
PHST- 2002/04/20 10:00 [pubmed]
PHST- 2002/06/20 10:01 [medline]
PHST- 2002/04/20 10:00 [entrez]
AID - S0006-4971(20)61029-1 [pii]
AID - 10.1182/blood.v99.9.3465 [doi]
PST - ppublish
SO  - Blood. 2002 May 1;99(9):3465-7. doi: 10.1182/blood.v99.9.3465.